Drug Profile
GL 0810
Alternative Names: GL-0810Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Mayo Clinic; University of Maryland, Baltimore
- Developer Gliknik
- Class Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Head and neck cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Head-and-neck-cancer in USA